Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:2394
Name ovarian cancer
Definition A female reproductive organ cancer that is located_in the ovary.
Source DiseaseOntology.org
Alt Ids DOID:2144 DOID:0060070 DOID:9595
Path disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer ovarian cancer

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
TP53 inact mut Adavosertib + Carboplatin + Paclitaxel ovarian cancer sensitive detail...
TP53 wild-type Ad.p53-DC vaccine ovarian cancer predicted - sensitive detail...
TP53 wild-type p53-SLP vaccine ovarian cancer no benefit detail...
PIK3CA mutant Temsirolimus ovarian cancer sensitive detail...
HRAS mutant Alpelisib + Binimetinib ovarian cancer predicted - sensitive detail...
PIK3CA H1047R PF-04691502 ovarian cancer sensitive detail...
BRAF V600E CI-1040 ovarian cancer sensitive detail...
PIK3CA mutant OSI-027 ovarian cancer sensitive detail...
PIK3CA amp Panulisib ovarian cancer sensitive detail...
PIK3CA H1047R MEN1611 ovarian cancer predicted - sensitive detail...
PIK3CA mutant MEN1611 ovarian cancer sensitive detail...
PIK3CA E545K MEN1611 ovarian cancer sensitive detail...
PIK3CA H1047R AZD8835 ovarian cancer sensitive detail...
TP53 R248Q ReACp53 ovarian cancer sensitive detail...
TP53 R248Q APR-246 + Cisplatin ovarian cancer sensitive detail...
TP53 loss ReACp53 ovarian cancer no benefit detail...
TP53 loss Cisplatin + LB-100 ovarian cancer sensitive detail...
TP53 inact mut Cisplatin + LB-100 ovarian cancer sensitive detail...
BRAF N486_P490del LY3009120 ovarian cancer sensitive detail...
BRAF N486_P490del Trametinib ovarian cancer sensitive detail...
BRAF N486_P490del Vemurafenib ovarian cancer resistant detail...
BRAF N486_P490del Dabrafenib ovarian cancer conflicting detail...
TP53 S241F Ganetespib ovarian cancer sensitive detail...
TP53 mutant Nutlin-3a ovarian cancer no benefit detail...
TP53 mutant Etoposide + Nutlin-3a ovarian cancer sensitive detail...
TP53 inact mut Cisplatin + Nutlin-3a ovarian cancer sensitive detail...
TP53 del Nutlin-3a ovarian cancer no benefit detail...
TP53 del Cisplatin + Nutlin-3a ovarian cancer sensitive detail...
TP53 del Etoposide + Nutlin-3a ovarian cancer sensitive detail...
PIK3CA amp XL147 ovarian cancer sensitive detail...
NRAS mutant Trametinib ovarian cancer sensitive detail...
PIK3CA mutant Buparlisib + Olaparib ovarian cancer sensitive detail...
PIK3CA H1047R A66 ovarian cancer sensitive detail...
PTEN loss OSI-027 ovarian cancer sensitive detail...
FGFR2 amp Aprutumab ixadotin ovarian cancer sensitive detail...
TP53 R280K APR-246 + Cisplatin ovarian cancer sensitive detail...
TP53 P151H APR-246 + Cisplatin ovarian cancer sensitive detail...
TP53 L111Q APR-246 + Cisplatin ovarian cancer sensitive detail...
TP53 Y163H APR-246 + Cisplatin ovarian cancer sensitive detail...
TP53 P278R APR-246 + Cisplatin ovarian cancer sensitive detail...
PIK3CA amp Voxtalisib ovarian cancer sensitive detail...
TP53 R175H NSC319726 ovarian cancer sensitive detail...
TP53 mutant Adavosertib + Carboplatin ovarian cancer predicted - sensitive detail...
TP53 Y163* Adavosertib + Carboplatin ovarian cancer predicted - sensitive detail...
TP53 P98fs TP53 R175C TP53 S215G Adavosertib + Carboplatin ovarian cancer predicted - resistant detail...
TP53 positive NU6027 + Temozolomide ovarian cancer predicted - sensitive detail...
TP53 over exp HLA-A2 p53:264-272 vaccine ovarian cancer predicted - sensitive detail...
BRAF V600E Vemurafenib ovarian cancer predicted - sensitive detail...
TP53 mutant AZD7648 + Olaparib ovarian cancer predicted - sensitive detail...
TP53 mutant Olaparib ovarian cancer predicted - sensitive detail...
TP53 mutant AZD7648 ovarian cancer sensitive detail...
PIK3CA mutant Perifosine ovarian cancer not predictive detail...
NRAS G12D BI-3406 ovarian cancer predicted - resistant detail...
PIK3CA E545K TAS-117 ovarian cancer predicted - sensitive detail...
FGFR2 positive Alofanib ovarian cancer predicted - sensitive detail...
BRAF N486_P490del Cobimetinib ovarian cancer sensitive detail...
BRAF N486_P490del PD-0325901 ovarian cancer sensitive detail...
BRAF N486_P490del GDC0879 ovarian cancer predicted - sensitive detail...
BRAF N486_P490del AZ628 ovarian cancer sensitive detail...
BRAF V600E Cobimetinib + Vemurafenib ovarian cancer predicted - sensitive detail...
RAD51C del Saruparib ovarian cancer sensitive detail...
MSH6 negative Pembrolizumab ovarian cancer sensitive detail...
MLH1 negative Pembrolizumab ovarian cancer sensitive detail...
RAD51C T132P Cisplatin + Paclitaxel ovarian cancer sensitive detail...
PIK3CA H1047R Temsirolimus ovarian cancer predicted - sensitive detail...
FGFR3 S249C Erdafitinib ovarian cancer predicted - sensitive detail...
RAD51C inact mut RP-3500 ovarian cancer predicted - sensitive detail...
PTEN R142fs PTEN L265fs TAS0612 ovarian cancer sensitive detail...
BRAF N486_P490del LXH 254 ovarian cancer sensitive detail...
BRAF N486_P490del Encorafenib ovarian cancer decreased response detail...
BRAF N486_P490del Sorafenib ovarian cancer sensitive detail...
BRAF N486_P490del Ulixertinib ovarian cancer predicted - sensitive detail...
BRAF N486_P490del LXH 254 + Trametinib ovarian cancer predicted - sensitive detail...
BRAF N486_P490del Sorafenib + Trametinib ovarian cancer predicted - sensitive detail...
NRAS Q61R Navitoclax + Trametinib ovarian cancer predicted - sensitive detail...
RAD51C mutant N/A ovarian cancer not applicable detail...
RAD51D mutant N/A ovarian cancer not applicable detail...
ATM mutant N/A ovarian cancer not applicable detail...
MLH1 mutant N/A ovarian cancer not applicable detail...
MSH6 mutant N/A ovarian cancer not applicable detail...
RAD51D K91Ifs*13 Olaparib ovarian cancer sensitive detail...
RAD51D K91Ifs*13 Niraparib ovarian cancer sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00194714 Phase Ib/II HER2 Vaccine Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab Completed USA 0
NCT00313599 Phase I Lapatinib + Paclitaxel Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors Completed USA 0
NCT00565851 Phase III Gemcitabine Docetaxel + Paclitaxel Carboplatin Bevacizumab Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting USA 2
NCT00892736 Phase I Veliparib Veliparib in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy Completed USA 0
NCT00993655 Phase III Cisplatin Paclitaxel Carboplatin Comparing Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Completed USA | GBR | ESP | CAN 0
NCT01031381 Phase II Bevacizumab + Everolimus Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer Completed USA 0
NCT01132014 Phase I Bevacizumab Dacarbazine Autologous OC-DC Vaccine in Ovarian Cancer Completed USA 0
NCT01218867 Phase Ib/II Anti-VEGFR2 CAR CD8 lymphocytes Cyclophosphamide Fludarabine Aldesleukin Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes Terminated USA 0
NCT01248949 Phase I Bevacizumab MEDI3617 Gemcitabine Carboplatin Paclitaxel A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors Completed USA 0
NCT01264432 Phase I Veliparib Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer Completed USA | CAN 0
NCT01286987 Phase I Talazoparib Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors Completed USA | GBR 0
NCT01292655 Phase I BMS-906024 Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors Completed USA | CAN | AUS 0
NCT01305213 Phase Ib/II Fosbretabulin Bevacizumab Bevacizumab With or Without Fosbretabulin Tromethamine in Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer Completed USA 0
NCT01312376 Phase I Fludarabine Cyclophosphamide Bevacizumab CD3/CD28 stimulated/primed autologous Ts OC-DC vaccine Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer Terminated USA 0
NCT01325441 Phase Ib/II Napabucasin + Paclitaxel A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Completed USA | CAN 0
NCT01357161 Phase II Carboplatin Adavosertib Paclitaxel A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004) Completed 0
NCT01366144 Phase I Paclitaxel Veliparib Carboplatin Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Active, not recruiting USA 0
NCT01384253 Phase I 212Pb-TCMC-Trastuzumab + Trastuzumab Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy Completed USA 0
NCT01445418 Phase I Olaparib Carboplatin AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer Completed USA 0
NCT01459380 Phase I Carboplatin Doxorubicin Veliparib Bevacizumab Veliparib, Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Completed USA 0
NCT01493505 Phase III Carboplatin Paclitaxel Trebananib TRINOVA-3 Terminated USA | NLD | ITA | GRC | ESP | DNK | DEU | CAN | BEL | AUT 4
NCT01551745 Phase II Bevacizumab + FANG vaccine Salvage Ovarian FANG Vaccine + Bevacizumab Completed USA 0
NCT01579812 Phase II Metformin Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients Completed USA 0
NCT01610206 Phase II Gemcitabine + Pazopanib Gemcitabine A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer Completed USA 0
NCT01616303 Phase II Carboplatin + Oregovomab + Paclitaxel Carboplatin + Paclitaxel A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer Completed USA 0
NCT01621542 Phase I WT2725 Clinical Study of WT2725 in Patients With Advanced Malignancies Completed USA 0
NCT01623349 Phase I Alpelisib + Olaparib Buparlisib + Olaparib Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer Completed USA 0
NCT01652079 Phase II Bevacizumab + NLG207 CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer Completed USA 0
NCT01663857 Phase Ib/II Ralimetinib Carboplatin + Gemcitabine A Study of LY2228820 for Recurrent Ovarian Cancer Completed USA | DEU | BEL | AUS 0
NCT01730118 Phase I HER2 Vaccine Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing Completed USA 0
NCT01831089 Phase I Bevacizumab + Lurbinectedin + Paclitaxel Lurbinectedin + Paclitaxel Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors Completed USA | ESP | CHE 0
NCT01847274 Phase III Niraparib A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer Completed USA | SWE | POL | NOR | ITA | ISR | HUN | GBR | FRA | ESP | DNK | DEU | CAN | BEL | AUT 0
NCT01874353 Phase III Olaparib Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy Active, not recruiting USA | POL | NLD | ITA | ISR | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS 4
NCT01920061 Phase I Dacomitinib + Gedatolisib Cisplatin + Gedatolisib Docetaxel + Gedatolisib A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC) Completed USA | ITA | GBR | ESP | CAN 0
NCT01928394 Phase Ib/II Ipilimumab + Nivolumab Cobimetinib + Ipilimumab + Nivolumab Nivolumab A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors Active, not recruiting USA | ITA | GBR | FIN | ESP | DNK | DEU | CAN 0
NCT01952249 Phase Ib/II Demcizumab Paclitaxel A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian Terminated USA 0
NCT01962948 Phase II Paclitaxel Ganetespib Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Terminated USA 0
NCT01966445 Phase I GSK2849330 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors Completed USA | NLD | AUS 0
NCT01968109 Phase I Nivolumab + Relatlimab Relatlimab Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors Active, not recruiting USA | NOR | NLD | ITA | GBR | FRA | FIN | ESP | DNK | DEU | CHE | CAN | AUT | AUS 1
NCT01972516 Phase II Tivozanib Tivozanib As Maintenance Therapy In GYN Terminated USA 0
NCT01989546 Phase Ib/II Talazoparib Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations Completed USA 0
NCT01995188 Phase I Bevacizumab + Carboplatin + DNIB0600A Carboplatin + DNIB0600A A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Patients With Ovarian Cancer Completed USA 0
NCT01999738 Phase I EC1456 Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors Completed USA 0
NCT02009449 Phase I Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Carboplatin Gemcitabine Docetaxel Pazopanib Capecitabine Paclitaxel Cisplatin Pegilodecakin Nab-paclitaxel A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors Active, not recruiting USA 0
NCT02014337 Phase I Eribulin + Mifepristone Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors Completed USA 0
NCT02035345 FDA approved Carboplatin Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment Terminated USA 0
NCT02046421 Phase I Mifepristone Carboplatin + Gemcitabine Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Completed USA 0
NCT02050009 Phase I Carboplatin + Metformin + Paclitaxel Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Withdrawn USA 0
NCT02068794 Phase Ib/II MV-NIS MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer Active, not recruiting USA 0
NCT02100007 Phase Ib/II ME-344 + Topotecan ME-344 Given in Combination With Hycamtin in Patients With Solid Tumors Terminated USA | GBR 0
NCT02117817 Phase I Buparlisib + Nab-paclitaxel Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer Withdrawn 0
NCT02118285 Phase I Aldesleukin Epacadostat Cyclophosphamide Fludarabine Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Completed USA 0
NCT02122809 Phase I Chiauranib Phase I Study of Chiauranib in Patients With Advanced Solid Tumors Completed 1
NCT02122861 Phase I ID-LV305 A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 Completed USA 0
NCT02124421 Phase II Carboplatin + Paclitaxel Cisplatin + Paclitaxel Outcomes in CRS/HIPEC as Initial Treatment of Ovarian, Fallopian Tube and Primary Peritoneal Cancer Active, not recruiting USA 0
NCT02199171 Phase I Carboplatin Heated Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Peritoneal Cancer Completed USA 0
NCT02203513 Phase II Prexasertib A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer Terminated USA 0
NCT02222922 Phase I Avelumab + Cofetuzumab pelidotin Fluconazole Cofetuzumab pelidotin A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors Completed USA | ESP 0
NCT02264678 Phase Ib/II Ceralasertib Carboplatin + Ceralasertib Ceralasertib + Durvalumab Ceralasertib + Olaparib Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents Recruiting USA | HUN | GBR | FRA | ESP | CAN | BEL | AUS 1
NCT02269293 Phase I Carboplatin + Paclitaxel + Selinexor Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers Completed USA 0
NCT02298959 Phase I Aflibercept + Pembrolizumab Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors Active, not recruiting USA | CAN 0
NCT02307240 Phase I CUDC-907 Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors Completed USA 0
NCT02312245 Phase II Topotecan Doxorubicin Paclitaxel Gemcitabine Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Completed USA 0
NCT02323191 Phase I Atezolizumab + Emactuzumab A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors Completed USA | FRA | ESP | BEL 0
NCT02326844 Phase II Talazoparib BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment Terminated USA 0
NCT02327078 Phase Ib/II Epacadostat + Nivolumab A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers Completed USA | GBR 0
NCT02335918 Phase Ib/II Nivolumab + Varlilumab A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors Completed USA 0
NCT02340611 Phase II Cediranib + Olaparib A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib Completed CAN 0
NCT02341625 Phase Ib/II BMS-986148 BMS-986148 + Nivolumab A Study of BMS-986148 in Patients With Select Advanced Solid Tumors Terminated USA | NLD | ITA | GBR | CAN | BEL | AUS 0
NCT02346747 Phase II FANG vaccine Phase II/III Trial of Maintenance Vigil for High Risk Stage III/IV Ovarian Cancer (VITAL) Active, not recruiting USA 0
NCT02346955 Phase I CM-24 CM-24 + Pembrolizumab Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) Terminated USA | ISR 0
NCT02349958 Phase II Mitomycin C Cisplatin Doxorubicin Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy Unknown status USA 0
NCT02387125 Phase I CMB305 A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 Terminated USA 0
NCT02417753 Phase II Danvatirsen AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites Terminated USA 0
NCT02419417 Phase Ib/II BMS986158 Paclitaxel Study of BMS-986158 in Subjects With Select Advanced Solid Tumors Completed USA | FRA | ESP | CAN | AUS 0
NCT02432690 Phase II Amcasertib A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation Terminated USA 0
NCT02432963 Phase I MVAp53 + Pembrolizumab Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy Active, not recruiting USA 0
NCT02433626 Phase I COTI-2 Cisplatin + COTI-2 Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (COTI2-101) Unknown status USA 0
NCT02437812 Phase II Paclitaxel Carboplatin Metformin Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma Unknown status USA 0
NCT02446600 Phase III Cediranib + Olaparib Olaparib Carboplatin + Gemcitabine + Paclitaxel + Pegylated liposomal doxorubicin Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting USA | CAN 2
NCT02452424 Phase Ib/II Pembrolizumab + Pexidartinib A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors Terminated USA 0
NCT02452775 Phase I OC-L Autologous OC-L Vaccine and Ovarian Cancer Terminated USA 0
NCT02476968 FDA approved Olaparib To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer (ORZORA) Completed POL | ITA | HUN | GBR | ESP | CZE | CAN | BGR 0
NCT02487095 Phase Ib/II Berzosertib Topotecan Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Lung Cancer Active, not recruiting USA 0
NCT02498600 Phase II Ipilimumab Nivolumab Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting USA 0
NCT02498665 Phase I DSP-7888 A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies Completed USA 0
NCT02502266 Phase II Topotecan Paclitaxel Doxorubicin Olaparib Cediranib Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting USA | CAN 3
NCT02520154 Phase II Carboplatin + Paclitaxel Pembrolizumab Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer Completed USA 0
NCT02554812 Phase Ib/II Avelumab + PF-04518600 Avelumab + PD 0360324 Avelumab + Utomilumab Avelumab + PF-04518600 + Utomilumab A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) Terminated USA | POL | GBR | FRA | CAN | AUS 2
NCT02558348 Phase Ib/II Anlotinib Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001) Terminated USA 0
NCT02575781 Phase I SAR428926 A Study of SAR428926 in Patients With Advanced Solid Tumors Completed FRA | ESP | DNK 0
NCT02575807 Phase Ib/II Epacadostat CRS-207 Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian, or Peritoneal Cancer Terminated USA | CAN 0
NCT02580058 Phase III Doxorubicin Avelumab A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer Completed USA | POL | NOR | NLD | ITA | ISR | IRL | HUN | GRC | GBR | FRA | ESP | DNK | CZE | CHE | CAN | BEL | AUT | AUS 6
NCT02584478 Phase Ib/II Anlotinib + Carboplatin + Paclitaxel Phase 1/2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) Active, not recruiting USA | ITA | GBR | ESP 2
NCT02595892 Phase II Berzosertib Gemcitabine Gemcitabine Hydrochloride Alone or With VX-970 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting USA 0
NCT02606305 Phase I Bevacizumab Carboplatin Doxorubicin Mirvetuximab Soravtansine Study of IMGN853 in Comb. With Bevacizumab, Carboplatin or PLD in Adults With FRa + Adv. EOC, Primary Peritoneal, Fallopian Tube, or Endometrial Cancer Completed USA | ESP | CAN | BEL 0
NCT02627430 Phase I Onalespib + Talazoparib Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer Withdrawn 0
NCT02627443 Phase II Carboplatin + Gemcitabine Berzosertib Carboplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting USA 0
NCT02628535 Phase I Obrindatamab Safety Study of MGD009 in B7-H3-expressing Tumors Terminated USA | CAN | AUS 0
NCT02631876 Phase II Paclitaxel + Pegylated liposomal doxorubicin Gemcitabine Topotecan Mirvetuximab Soravtansine PH2 Study of IMGN853 vs Investigator's Choice of Chemo in Adults With FRa+ Adv. EOC, Primary Peritoneal or Primary Fallopian Tube Cancer Completed USA | ITA | IRL | GBR | FRA | ESP | CZE | CHE | CAN | BEL 3
NCT02632448 Phase Ib/II Gemcitabine + LY2880070 LY2880070 A Study of LY2880070 in Participants With Advanced or Metastatic Cancer Recruiting USA | POL | HRV | CAN 0
NCT02646319 Phase I Nab-rapamycin Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations Completed USA 0
NCT02649673 Phase Ib/II LCL161 + Topotecan LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies Terminated USA 0
NCT02655016 Phase III Niraparib A Study of Niraparib Maintenance Treatment in Patients With HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy Active, not recruiting USA | SWE | POL | NOR | ITA | ISR | IRL | HUN | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BEL 2
NCT02658214 Phase I Cisplatin + Durvalumab + Fluorouracil + Tremelimumab Durvalumab + Gemcitabine + Nab-paclitaxel + Tremelimumab Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin + Tremelimumab Carboplatin + Durvalumab + Nab-paclitaxel + Tremelimumab Carboplatin + Durvalumab + Etoposide + Tremelimumab Carboplatin + Durvalumab + Paclitaxel + Tremelimumab Carboplatin + Durvalumab + Gemcitabine + Tremelimumab Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors Completed 2
NCT02681237 Phase I Cediranib + Olaparib A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer Completed CAN 0
NCT02725489 Phase II Durvalumab + FANG vaccine Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers Completed USA 0
NCT02734004 Phase Ib/II Durvalumab + Olaparib Bevacizumab + Durvalumab + Olaparib A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA) Active, not recruiting USA | NLD | ISR | GBR | FRA | CHE 1
NCT02737787 Phase I Nivolumab + WT1 vaccine Nivolumab + NY-ESO-1 peptide vaccine A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer Completed USA 0
NCT02760797 Phase I Emactuzumab + Selicrelumab A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors Completed USA | FRA | BEL 0
NCT02762981 Phase Ib/II Nab-paclitaxel + Relacorilant Study to Evaluate CORT125134 in Combination With Nab-paclitaxel in Patients With Solid Tumors Completed USA 0
NCT02799095 Phase I ALKS 4230 A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors Completed USA | POL | ESP | CAN | BEL | AUS 1
NCT02839707 Phase II Atezolizumab + Bevacizumab + Pegylated liposomal doxorubicin Atezolizumab + Pegylated liposomal doxorubicin Bevacizumab + Pegylated liposomal doxorubicin Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting USA 1
NCT02880371 Phase Ib/II ARRY-382 + Pembrolizumab A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors Terminated USA 0
NCT02923349 Phase Ib/II INCAGN01949 A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors Completed USA | GBR | ESP | CHE 0
NCT02950064 Phase I BTP-114 A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations Unknown status USA 0
NCT02952248 Phase I Ezabenlimab A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours Completed USA | GBR | CAN 0
NCT02953782 Phase Ib/II Cetuximab + Hu5F9-G4 Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer Completed USA 0
NCT02996825 Phase I Gemcitabine + Mirvetuximab Soravtansine Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer Completed USA 0
NCT03023319 Phase I Bosutinib + Pemetrexed Disodium Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors Completed USA 0
NCT03026062 Phase II Tremelimumab Durvalumab + Tremelimumab Durvalumab Durvalumab and Tremelimumab in Combo Versus Sequential Active, not recruiting USA 0
NCT03029598 Phase Ib/II Carboplatin + Pembrolizumab Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed USA 0
NCT03030287 Phase I Navicixizumab + Paclitaxel A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer Completed USA 0
NCT03056833 Phase I Carboplatin + Paclitaxel + Ribociclib Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer Completed USA 0
NCT03076372 Phase I MM-310 A Study Evaluating MM-310 in Patients With Solid Tumors Unknown status USA 0
NCT03132922 Phase I afamitresgene autoleucel MAGE-A4c1032T for Multi-Tumor Active, not recruiting USA | CAN 0
NCT03150810 Phase Ib/II Pamiparib + Temozolomide Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors Completed USA | GBR | ESP | AUS 0
NCT03154281 Phase I Everolimus + Niraparib Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Ovarian and Breast Completed USA 0
NCT03162627 Phase I Olaparib + Selumetinib Selumetinib and Olaparib in Solid Tumors Active, not recruiting USA 0
NCT03188965 Phase I Elimusertib First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas Completed USA | GBR | CHE | CAN 3
NCT03199586 Phase I NP-G2-044 Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma) Completed USA 0
NCT03206177 Phase I Carboplatin + Galunisertib + Paclitaxel Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary Completed USA 0
NCT03239145 Phase I Pembrolizumab + Trebananib Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor Active, not recruiting USA 0
NCT03264664 Phase I E7386 Study of E7386 in Participants With Selected Advanced Neoplasms Active, not recruiting USA | GBR 0
NCT03283943 Phase I Durvalumab PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers. Unknown status CAN 0
NCT03292172 Phase I Atezolizumab + TEN-010 A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer Terminated USA | GBR | DNK | CAN | AUS 0
NCT03294694 Phase I Fulvestrant + Ribociclib + Spartalizumab Ribociclib + Spartalizumab Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer Terminated USA 0
NCT03329950 Phase I CDX-1140 + CDX-301 CDX-1140 A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors Completed USA 0
NCT03330405 Phase II Avelumab + Talazoparib Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors Terminated USA | HUN | GBR | DNK | CAN | BEL | AUS 2
NCT03342417 Phase II Ipilimumab + Nivolumab Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients Terminated USA 0
NCT03353831 Phase III Bevacizumab + Paclitaxel Bevacizumab + Pegylated liposomal doxorubicin Atezolizumab + Bevacizumab + Pegylated liposomal doxorubicin Atezolizumab + Bevacizumab + Paclitaxel Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer Active, not recruiting SWE | NOR | LTU | FRA | FIN | EST | ESP | DNK | DEU | CHE | BEL | AUT 0
NCT03363776 Phase Ib/II BMS-986277 BMS-986277 + Nivolumab An Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers Terminated USA | CAN 0
NCT03363893 Phase Ib/II Samuraciclib Fulvestrant + Samuraciclib Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies Completed USA | GBR 0
NCT03412877 Phase II Aldesleukin + Cyclophosphamide + Fludarabine + iTCR-transduced PBL Aldesleukin + Cyclophosphamide + Fludarabine + iTCR-transduced PBL + Pembrolizumab Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer Recruiting USA 0
NCT03430700 Phase II Pembrolizumab Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer (PROMPT) Active, not recruiting GBR 0
NCT03449108 Phase II Cyclophosphamide + Fludarabine + Interleukin-12 + LN-145 + Mesna Iovance Alliance: LN-145 Across Multiple Tumor Types Active, not recruiting USA 0
NCT03456700 Phase II Auranofin + Sirolimus Auranofin and Sirolimus in Treating Participants With Ovarian Cancer Active, not recruiting USA 0
NCT03458221 Phase II Itraconazole Everolimus Letrozole Bicalutamide Signal TrAnsduction Pathway Activity Analysis in OVarian cancER (STAPOVER) Recruiting NLD 0
NCT03508570 Phase I Nivolumab Ipilimumab + Nivolumab Nivolumab With or Without Ipilimumab in Treating Participants With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis Active, not recruiting USA 0
NCT03538028 Phase I INCAGN02385 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies Completed USA 0
NCT03539328 Phase II Gemcitabine + Paclitaxel + Pegylated liposomal doxorubicin Gemcitabine + Paclitaxel + Pegylated liposomal doxorubicin + Pembrolizumab Study on MK-3475 Plus Chemotherapy Versus Chemotherapy Alone in Recurrent, Platinum-resistant Ovarian Cancer (MITO27) Unknown status ITA 0
NCT03552471 Phase I Mirvetuximab Soravtansine + Rucaparib Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Active, not recruiting USA 0
NCT03556228 Phase I VMD-928 Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma Recruiting USA 1
NCT03565445 Phase I ASP1948 + Nivolumab ASP1948 A Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects With Advanced Solid Tumors Completed USA | ITA | GBR | ESP | CAN 4
NCT03610490 Phase II Aldesleukin + Cyclophosphamide + Fludarabine + MDA autologous tumor-infiltrating lymphocytes Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma Terminated USA 0
NCT03621982 Phase I Camidanlumab tesirine Study of ADCT-301 in Patients With Selected Advanced Solid Tumors Terminated USA | GBR | BEL 0
NCT03628677 Phase I AB154 AB154 + Zimberelimab A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies Active, not recruiting USA | AUS 0
NCT03629756 Phase I Etrumadenant + Zimberelimab A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies Completed USA | AUS 0
NCT03639246 Phase Ib/II AVB-S6-500 + Paclitaxel AVB-S6-500 + Pegylated liposomal doxorubicin Paclitaxel Pegylated liposomal doxorubicin Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer Completed USA 0
NCT03663712 Phase I Talimogene laherparepvec Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies (TEMPO) Completed USA 0
NCT03665285 Phase Ib/II NC318 A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors Completed USA 0
NCT03667716 Phase I COM701 COM701 + Nivolumab COM701 in Subjects With Advanced Solid Tumors Completed USA 0
NCT03674567 Phase Ib/II FLX475 + Pembrolizumab FLX475 Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab Active, not recruiting USA | AUS 4
NCT03700294 Phase I ADCT-601 Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors Terminated USA 0
NCT03717415 Phase Ib/II Carboplatin + Rebastinib A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors Completed USA 0
NCT03719326 Phase I Eganelisib + Etrumadenant + Pegylated liposomal doxorubicin Etrumadenant + Pegylated liposomal doxorubicin A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies Completed USA | AUS 0
NCT03733990 Phase Ib/II FP-1305 A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) Completed USA | NLD | GBR | FRA | FIN | ESP 0
NCT03761914 Phase Ib/II Galinpepimut-S Galinpepimut-S + Pembrolizumab Pembrolizumab Sargramostim Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers Active, not recruiting USA 0
NCT03784378 Phase I RXDX-105 Continued Access to RXDX-105 Completed USA 0
NCT03797326 Phase II Lenvatinib + Pembrolizumab Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) Completed USA | ITA | ISR | GBR | FRA | ESP | DEU | CHE | CAN | AUS | ARG 6
NCT03815682 Phase I Pembrolizumab + RPTR-147 RPTR-147 RPTR-147 in Patients With Selected Solid Tumors and Lymphomas Terminated USA 0
NCT03872947 Phase I Pembrolizumab + TRK-950 Carboplatin + Gemcitabine + TRK-950 Imiquimod + TRK-950 Paclitaxel + Ramucirumab + TRK-950 Nivolumab + TRK-950 Cisplatin + Gemcitabine + TRK-950 Fluorouracil + Irinotecan + Leucovorin + TRK-950 A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors Recruiting USA | FRA 0
NCT03875820 Phase I Defactinib + RO5126766 Phase I Trial of Defactinib and VS-6766. (FRAME) Active, not recruiting GBR 0
NCT03891576 Phase II Niraparib Newton Study (NEW Dosing mainTenance Therapy Ovarian caNcer) (Newton) Active, not recruiting ITA | DEU 0
NCT03907527 Phase I PRGN-3005 Modified Immune Cells (Autologous CAR T Cells) in Treating Patients With Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer Active, not recruiting USA 0
NCT03936959 Phase I LY3434172 A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer Completed USA | FRA | BEL | AUS 1
NCT03944902 Phase I Niraparib + Telaglenastat CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer Patients (BRCA) Terminated USA 0
NCT03968406 Phase I Talazoparib Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers Recruiting USA 0
NCT03970382 Phase I NeoTCR-P1 T-cells + Nivolumab NeoTCR-P1 T-cells A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors Suspended USA 0
NCT03990233 Phase I Effi-DEM Effi-DEM + Ezabenlimab A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours Active, not recruiting FRA | BEL 0
NCT03992131 Phase Ib/II Lucitanib + Rucaparib Rucaparib + Sacituzumab govitecan-hziy A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor (SEASTAR) Terminated USA 0
NCT03997968 Phase Ib/II CYT01B A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors Active, not recruiting USA 0
NCT04041128 Phase I Olaparib PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer Completed USA 0
NCT04044859 Phase I afamitresgene autoleucel afamitresgene autoleucel + Pembrolizumab afamitresgene autoleucel + Nivolumab ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) Recruiting USA | ESP | CAN | BEL 0
NCT04068896 Phase I NGM120 Study of NGM120 in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy Completed USA 0
NCT04091204 Phase II Olaparib Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational Study (MITO 31) Recruiting ITA 0
NCT04095273 Phase I Elimusertib + Pembrolizumab Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the ATR Inhibitor BAY1895344 in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug Completed USA | GBR | ESP | DEU | CHE 0
NCT04105335 Phase I CEBPA-51 + Pembrolizumab A Study of MTL-CEBPA in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumours (TIMEPOINT) (TIMEPOINT) Active, not recruiting GBR 0
NCT04134312 Phase I MVA-BN-Brachyury A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer Completed USA 0
NCT04148937 Phase I LY3475070 LY3475070 + Pembrolizumab A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer Completed USA | GBR | AUS 0
NCT04152018 Phase I PF-06801591 + PF-06940434 PF-06940434 Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. Active, not recruiting USA | SVK | AUS 2
NCT04169841 Phase II Durvalumab + Olaparib + Tremelimumab Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment (GUIDE2REPAIR) Active, not recruiting FRA 0
NCT04235101 Phase I Niraparib + Trastuzumab Duocarmazine Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors Completed NLD | GBR | BEL 0
NCT04243499 Phase I ICT01 First-in-Human Study of ICT01 in Patients With Advanced Cancer (EVICTION) Recruiting USA | GBR | FRA | ESP | DEU | BEL 0
NCT04244552 Phase I ATRC-101 First-in-Human Dose Escalation Trial of ATRC-101 in Adults With Advanced Solid Malignancies Terminated USA 0
NCT04250597 Phase I GNX102 Study of GNX102 in Patients With Advanced Solid Tumors Terminated USA 1
NCT04259450 Phase Ib/II AFM24 Study to Assess AFM24 in Advanced Solid Cancers Completed USA | GBR | ESP | DEU 1
NCT04260802 Phase Ib/II OC-001 + unspecified PD-L1 antibody OC-001 + unspecified PD-1 antibody OC-001 A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers Recruiting CAN 0
NCT04261465 Phase II Carboplatin + Olaparib + Paclitaxel NUVOLA TRIAL Open-label Multicentre Study (NUVOLA) Unknown status ITA 0
NCT04282018 Phase Ib/II BGB-10188 + Zanubrutinib BGB-10188 + Tislelizumab BGB-10188 Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab Completed AUS 1
NCT04367675 Phase I INO-5401 INO-5401 + INO-9012 INO 5401 Vaccination in BRCA1/2 Mutation Carriers Recruiting USA 0
NCT04375956 Phase II Pembrolizumab Study on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary Peritoneal Cancer Patients (MITO 27) Recruiting ITA 0
NCT04377087 Phase II Olaparib Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer Terminated USA 0
NCT04387227 Phase II Carboplatin + Pembrolizumab Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting USA 0
NCT04389632 Phase I SGN-B6A A Study of SGN-B6A in Advanced Solid Tumors Recruiting USA | GBR | FRA | ESP | CHE 1
NCT04395079 Phase II Tremelimumab Durvalumab Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies Active, not recruiting USA 0
NCT04396821 Phase I TST001 A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors Active, not recruiting USA 0
NCT04406623 Phase I SL-172154 Phase 1 Study of SL-172154 (SIRPalpha-Fc-CD40L) in Subjects With Ovarian Cancer Completed USA 0
NCT04423029 Phase Ib/II DF6002 DF6002 + Nivolumab A Study to Assess DF6002 (BMS-986415) Alone and in Combination With Nivolumab in Participants With Locally Advanced or Metastatic Solid Tumors Recruiting USA | FRA | ESP | AUS 0
NCT04430842 Phase I QBS10072S Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S Completed AUS 0
NCT04434482 Phase I Senaparib + Temozolomide IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer Completed USA | AUS 3
NCT04491942 Phase I Cisplatin + Elimusertib Cisplatin + Elimusertib + Gemcitabine Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer Active, not recruiting USA | CAN 0
NCT04493619 Phase Ib/II Carboplatin + PLX2853 PLX2853 PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer Terminated USA | CAN 0
NCT04502602 Phase I Neratinib + Niraparib Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer (iNNOVATE) Recruiting USA 0
NCT04511845 Phase I SPYK04 A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion). Active, not recruiting USA 1
NCT04514484 Phase I Cabozantinib + Nivolumab Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Active, not recruiting USA 0
NCT04550494 Phase II Talazoparib Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations Recruiting USA 0
NCT04561362 Phase Ib/II BT8009 BT8009 + Pembrolizumab Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies Recruiting USA | ITA | GBR | FRA | ESP | CAN 0
NCT04580485 Phase I INCB106385 + Retifanlimab INCB106385 INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors Completed USA | ITA | GBR | FRA | ESP | BEL 0
NCT04592653 Phase Ib/II ALKS 4230 ALKS 4230 + Pembrolizumab Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3) (ARTISTRY-3) Active, not recruiting USA | ESP 0
NCT04602117 Phase I Paclitaxel + Trastuzumab Duocarmazine Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer Withdrawn USA 0
NCT04606381 Phase I Amivantamab-vmjw + Lazertinib Amivantamab-vmjw + Lazertinib + rHuPH20 Amivantamab-vmjw Amivantamab-vmjw + rHuPH20 A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies (PALOMA) Active, not recruiting USA | GBR | CAN 1
NCT04608409 Phase I Lapatinib + Paclitaxel Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer Active, not recruiting USA 0
NCT04609579 Phase I SNX281 Pembrolizumab + SNX281 Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma Terminated USA 0
NCT04616534 Phase I Elimusertib + Gemcitabine Testing the Addition of an Anti-cancer Drug, BAY 1895344 ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors Active, not recruiting USA 0
NCT04641247 Phase II Niraparib A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study Active, not recruiting USA | ITA | ISR | FRA | ESP | DNK | CAN | AUT 0
NCT04644289 Phase II Olaparib Durvalumab + Olaparib WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC (WoO) Recruiting DEU 0
NCT04665921 Phase I SGN-STNV A Study of SGN-STNV in Advanced Solid Tumors Terminated USA | ITA | GBR | FRA | ESP | CAN 0
NCT04673448 Phase I Dostarlimab-gxly + Niraparib Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer Recruiting USA 0
NCT04676334 Phase III Rucaparib CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib (CATCH-R) Completed POL | ITA | ISR | GBR | CAN 1
NCT04679064 Phase III Bevacizumab + Gemcitabine Dostarlimab-gxly + Niraparib Pegylated liposomal doxorubicin Bevacizumab + Topotecan Paclitaxel Topotecan Bevacizumab + Paclitaxel Bevacizumab + Pegylated liposomal doxorubicin Gemcitabine Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment (NItCHE-MITO33) Recruiting ITA 0
NCT04682431 Phase I Pembrolizumab + PY159 PY159 A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors Terminated USA 0
NCT04691375 Phase I Pembrolizumab + PY314 PY314 A Study of PY314 in Subjects With Advanced Solid Tumors Terminated USA 0
NCT04695847 Phase I M1231 M1231 in Participants With Solid Tumors Completed USA | CAN 0
NCT04707248 Phase I Raludotatug deruxtecan A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors Recruiting USA 1
NCT04711161 Phase I GRN-300 GRN-300 + Paclitaxel First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers. Suspended USA 0
NCT04731467 Phase Ib/II CM-24 + Nivolumab CM-24 + Nab-paclitaxel + Nivolumab A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors Active, not recruiting USA | ISR | ESP 0
NCT04739800 Phase II Paclitaxel + Pegylated liposomal doxorubicin + Topotecan Cediranib + Durvalumab Cediranib + Olaparib Cediranib + Durvalumab + Olaparib Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents Active, not recruiting USA 1
NCT04752826 Phase Ib/II BI-1808 + Pembrolizumab BI-1808 BI-1808 as a Single Agent and With Pembrolizumab in Treatment of Advanced Malignancies(Keynote-D20) Recruiting USA | SWE | HUN | GBR | DNK 1
NCT04787042 Phase Ib/II Pembrolizumab + ST-067 ST-067 Obinutuzumab + ST-067 Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 Active, not recruiting USA 0
NCT04826198 Phase Ib/II AsiDNA + Niraparib Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to Niraparib in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With Niraparib (REVOCAN) Recruiting FRA 0
NCT04837196 Phase Ib/II ASP7517 + Pembrolizumab ASP7517 Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen Completed USA 0
NCT04851834 Phase Ib/II Cisplatin + NTX-301 NTX-301 NTX-301 + Temozolomide Carboplatin + NTX-301 NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma Terminated AUS 0
NCT04890613 Phase I CX-5461 Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation Recruiting USA | CAN 0
NCT04907968 Phase Ib/II Carboplatin + XMT-1536 Study of Upifitamab Rilsodotin in Combination With Other Agent(s) in Participants With High-grade Serous Ovarian Cancer (UPGRADE) Terminated USA 0
NCT04925284 Phase I XB002 Nivolumab + XB002 Study of XB002 in Subjects With Solid Tumors (JEWEL-101) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | BEL | AUS 1
NCT04939701 Phase Ib/II ASP0739 + Pembrolizumab ASP0739 Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants Terminated USA 0
NCT04969835 Phase I AVA6000 A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours Recruiting USA | GBR 0
NCT04972981 Phase I ADCT-901 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors Active, not recruiting USA | GBR | ESP 0
NCT04992013 Phase II Niraparib Niraparib in Tumors Metastatic to the CNS Recruiting USA 0
NCT05000294 Phase Ib/II Atezolizumab + Tivozanib Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types Recruiting USA 0
NCT05001282 Phase Ib/II ELU001 A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRalpha) Terminated USA 0
NCT05001347 Phase II Uliledlimab A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ) in Patients With Ovarian Cancer and Selected Solid Tumors Completed USA 0
NCT05038150 Phase I SGN1 Study of SGN1 in Patients With Advanced Solid Tumor Recruiting USA 1
NCT05041972 Phase II ARX-788 ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02) Withdrawn USA 0
NCT05057013 Phase Ib/II HMBD-001 HMBD-001 in Advanced HER3 Positive Solid Tumours Recruiting GBR 0
NCT05067972 Phase I PF-07260437 A Study of PF-07260437 in Advanced or Metastatic Solid Tumors (C4431001) Terminated USA 1
NCT05071937 Phase II Talazoparib + ZEN-3694 ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer Recruiting USA 0
NCT05082025 Phase II Copanlisib + Fulvestrant Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations Active, not recruiting USA 0
NCT05092373 Phase I Cabozantinib Atezolizumab + Nab-paclitaxel Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax Recruiting USA 0
NCT05098405 Phase I MP0317 First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors Terminated NLD | FRA 0
NCT05103345 Phase I SGN1 Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor Recruiting 2
NCT05104515 Phase I OVM-200 First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine Recruiting GBR 0
NCT05118841 Phase I ZX-4081 Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors Unknown status USA 0
NCT05123482 Phase Ib/II AZD8205 First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic Solid Malignancies Recruiting USA | POL | NLD | ITA | HUN | GBR | ESP | CAN | BEL | AUS 5
NCT05180474 Phase Ib/II GEN1047 GEN1047 for Solid Tumors - First in Human (FIH) Trial Active, not recruiting USA | POL | NLD | ITA | GBR | FRA | ESP | DNK | BEL 0
NCT05185947 Phase II Nilotinib + Paclitaxel Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Ovarian, Colorectal, or Appendiceal Cancer Recruiting USA 0
NCT05200364 Phase I Bevacizumab + Luveltamab Tazevibulin A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer Recruiting USA 0
NCT05200559 Phase Ib/II E7777 + Pembrolizumab T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors Recruiting USA 0
NCT05208762 Phase I SGN-PDL1V A Study of SGN-PDL1V in Advanced Solid Tumors Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL 0
NCT05229900 Phase I SGN-ALPV A Study of SGN-ALPV in Advanced Solid Tumors Terminated USA | SWE | GBR | ESP | CAN 0
NCT05252390 Phase Ib/II NUV-868 NUV-868 + Olaparib Enzalutamide + NUV-868 NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors Recruiting USA | AUS 0
NCT05252416 Phase Ib/II BLU-222 + Carboplatin BLU-222 + Fulvestrant + Ribociclib BLU-222 + Fulvestrant (VELA) Study of BLU-222 in Advanced Solid Tumors Recruiting USA | ITA | GBR 0
NCT05255471 Phase III Carboplatin + Paclitaxel Olaparib Carboplatin + Pegylated liposomal doxorubicin Carboplatin + Gemcitabine MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients. (MITO 35B) Recruiting ITA 0
NCT05256381 Phase II Pembrolizumab + SOT101 A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors Active, not recruiting USA | POL | ITA | HUN | FRA | ESP | CZE | BEL 1
NCT05259696 Phase Ib/II E-602 E-602 + Pembrolizumab Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) (GLIMMER-01) Active, not recruiting USA 0
NCT05262530 Phase Ib/II BNT142 Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors Recruiting USA | GBR | ESP 1
NCT05263180 Phase I EMB-09 A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors. Recruiting AUS 1
NCT05271318 Phase I Pembrolizumab + TILT-123 Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Ovarian Cancer (PROTA) Recruiting USA | FIN 0
NCT05276973 Phase I Carboplatin + Ipatasertib + Paclitaxel Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer Recruiting USA 0
NCT05281471 Phase III Bevacizumab + Carboplatin Bevacizumab + Cisplatin Bevacizumab + Carboplatin + GL-ONC1 Bevacizumab + Cisplatin + GL-ONC1 Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Platinum-doublet + Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (OnPrime) Recruiting USA 0
NCT05293496 Phase I MGC018 + MGD019 A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors Recruiting USA 0
NCT05295589 Phase II Topotecan Pegylated liposomal doxorubicin Copanlisib + Olaparib Paclitaxel Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy Withdrawn USA 0
NCT05298592 Phase I BMS-986406 + Nivolumab BMS-986406 A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors Completed USA | ESP | BEL | ARG 2
NCT05306444 Phase I HBM7008 CLN-418 Study on Subjects With Advanced Solid Tumors Completed USA | AUS 0
NCT05307874 Phase Ib/II Aldesleukin + ICT01 Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors (EVICTION-2) Recruiting FRA 0
NCT05358379 Phase Ib/II CYC140 A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma Recruiting USA | ESP 1
NCT05360680 Phase I CUE-102 A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers Active, not recruiting USA 0
NCT05368506 Phase I ZN-c3 ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer Withdrawn 0
NCT05394103 Phase Ib/II Q901 Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors Recruiting USA 1
NCT05394675 Phase I DS-9606a A Study of DS-9606a in Patients With Advanced Solid Tumors Recruiting USA | GBR 0
NCT05417594 Phase Ib/II AZD9574 AZD9574 + Temozolomide Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies (CERTIS1) Recruiting USA | SWE | GBR | ESP | DEU | AUS 1
NCT05427487 Phase I IVX037 Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours Recruiting AUS 0
NCT05496595 Phase I DCBY02 DCBY02 or DCSZ11 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors Terminated USA 0
NCT05500508 Phase Ib/II AMXT1501 + Eflornithine Oral AMXT 1501 Dicaprate in Combination With IV DFMO Active, not recruiting USA | AUS 0
NCT05523440 Phase II Bevacizumab + Niraparib Niraparib Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation Recruiting USA 0
NCT05554328 Phase II Selumetinib Olaparib + Selumetinib Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial Recruiting USA 1
NCT05568680 Phase I SynKIR-110 SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma Recruiting USA 0
NCT05572684 Phase Ib/II NC410 + Pembrolizumab A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors Recruiting USA 0
NCT05607498 Phase I EMB-07 First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors Recruiting AUS 1
NCT05613088 Phase II Paclitaxel + Pegylated liposomal doxorubicin + Topotecan MORAb-202 A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Recruiting USA | ITA | ISR | ESP | BEL | AUS 3
NCT05617755 Phase I AB-1015 AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer Active, not recruiting USA 0
NCT05642780 Phase II Pembrolizumab + SKB264 SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors Recruiting USA | POL | CAN | BEL | AUS 1
NCT05642949 Phase Ib/II MHB036C Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors Not yet recruiting AUS 0
NCT05650203 Phase I JS006 + JS009 + Toripalimab-tpzi JS009 A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies Withdrawn 0
NCT05652855 Phase Ib/II MHB088C Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors Not yet recruiting AUS 0
NCT05662397 Phase Ib/II HST-1011 Cemiplimab + HST-1011 A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody Recruiting USA 0
NCT05683418 Phase I TOS-358 A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With Select Solid Tumors Recruiting USA 0
NCT05684965 Phase I XTX301 XTX301 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT05694715 Phase I Irinotecan + Niraparib Combination Therapy in Cancers With Mutations in DNA Repair Genes Recruiting USA 0
NCT05719558 Phase I ASP1002 A Study of ASP1002 in Adults for Treatment of Solid Tumors Recruiting USA 0
NCT05720117 Phase I PYX-201 Study of PYX-201 in Solid Tumors Recruiting USA | ESP | BEL 0
NCT05733000 Phase II CPI-613 + Gemcitabine + Hydroxychloroquine CPI-613 + Hydroxychloroquine CPI-613 + Gemcitabine CPI-613 + Fluorouracil + Hydroxychloroquine CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors Recruiting USA 0
NCT05746897 Phase I NM1F + Pembrolizumab NM1F A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors Recruiting USA 0
NCT05756907 Phase Ib/II Atezolizumab + SON-1010 SON-1010 Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer Recruiting USA | AUS 0
NCT05785754 Phase I DCSZ11 DCSZ11 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors Recruiting USA | AUS 2
NCT05821777 Phase Ib/II LB101 A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors Recruiting USA | FRA 0
NCT05848739 Phase I ST316 A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors Recruiting USA 0
NCT05875168 Phase Ib/II DS-3939a First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors Recruiting USA | FRA | ESP | BEL 1
NCT05891171 Phase I AB598 + Carboplatin + Pemetrexed Disodium + Zimberelimab AB598 AB598 + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers (ARC-25) Recruiting USA | AUS 0
NCT05922930 Phase Ib/II TROP2-CAR/IL15-transduced CBNK cells Cyclophosphamide + Fludarabine Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer Recruiting USA 0
NCT05932862 Phase I ISM3091 First-in Human Phase I Study of ISM3091 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT05934539 Phase Ib/II ALG.APV-527 ALG.APV-527 First-in-human Study Recruiting USA 0
NCT05942300 Phase I Carboplatin + Tulmimetostat CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer Recruiting USA 0
NCT05947474 Phase I ORB-011 ORB-011 In Patients With Advanced Solid Tumors (ORB) Recruiting USA 0
NCT05964361 Phase Ib/II IL15-TransDC First-in-human Interleukin-15-transpresenting Wilms' Tumor Protein 1-targeting Autologous Dendritic Cell Vaccination in Cancer Patients Recruiting BEL 0
NCT05985083 Phase I IMM47 A Study Of IMM47 In Subjects With Advanced Solid Tumors Recruiting AUS 0
NCT05989724 Phase I SON-DP A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors Recruiting USA 0
NCT06003231 Phase II Disitamab vedotin A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 Recruiting USA | ITA | GBR | ESP | CAN | AUS 1
NCT06014502 Phase I IMGS-001 Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors Recruiting USA 0
NCT06036121 Phase I ADRX-0706 A Study of ADRX-0706 in Select Advanced Solid Tumors Recruiting USA 1
NCT06051695 Phase Ib/II A2B694 A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Subjects With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression (EVEREST-2) Recruiting USA 0
NCT06052852 Phase Ib/II BDC-3042 + Pembrolizumab BDC-3042 Study of BDC-3042 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Malignancies Recruiting USA 0
NCT06056323 Phase Ib/II HB0045 A Study of HB0045 Injection in Patients With Advanced Solid Tumors Recruiting USA 0
NCT06072781 Phase III Paclitaxel Pegylated liposomal doxorubicin Defactinib + RO5126766 Topotecan Anastrozole Letrozole A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer (RAMP 301) Recruiting USA | ITA | GBR | FRA | ESP | CAN | AUS 0
NCT06090266 Phase Ib/II Cemiplimab + OR502 A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents Recruiting USA 0
NCT06107868 Phase I Carboplatin + Paclitaxel + RP-6306 Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer (GyneRep) Active, not recruiting CAN 0
NCT06108479 Phase I DF6215 Study of DF6215 in Patients With Advanced Solid Tumors Recruiting USA | FRA | AUS 0
NCT06120972 Phase II Olaparib Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency Recruiting USA 0
NCT06154291 Phase Ib/II XON7 FIH XON7 in Advanced/Metastatic Solid Tumors (FIPO23) Recruiting FRA | BEL 0
NCT06171178 Phase I ASP1012 + Pembrolizumab ASP1012 A Study of ASP1012 in Adults With Solid Tumors Recruiting USA 0
NCT06171789 Phase Ib/II PRO1107 PRO1107 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT06234423 Phase I CUSP06 A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors Recruiting USA 0
NCT06238479 Phase I LY4101174 A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors Recruiting USA | ESP | BEL | AUS 1
NCT06242470 Phase I MGC026 A Study of MGC026 in Participants With Advanced Solid Tumors Recruiting USA | AUS 0
NCT06253520 Phase I Cyclophosphamide + Fludarabine Aldesleukin + Anti-KRAS G12V TCR cells + GRT-C903 + GRT-R904 Aldesleukin + Anti-KRAS G12D TCR cells + GRT-C903 + GRT-R904 Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer Recruiting USA 0
NCT06264921 Phase I NKT3447 A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors Recruiting USA 0
NCT06274437 Phase I BND-35 + Cetuximab BND-35 + Nivolumab BND-35 A Study of BND-35 in Participants With Advanced Solid Tumors Recruiting ISR 0
NCT06276491 Phase I XmAb541 Phase 1, Safety and Tolerability Study of XmAb®541 in Advanced Solid Tumors Recruiting USA 0
NCT06279130 Phase II Balstilimab Balstilimab + Botensilimab Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations (NEOASIS) Recruiting NLD 0
NCT06293898 Phase I BL-M07D1 Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors Recruiting USA 0
NCT06303505 Phase Ib/II TUB-040 FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC (NAPISTAR1-01) Recruiting USA | ESP | DEU | BEL 1
NCT06342986 FT536 Cyclophosphamide + Fludarabine Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Recruiting USA 0
NCT06380816 Phase Ib/II UCB4594 A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer Recruiting GBR 0
NCT06399757 Phase Ib/II APL-5125 A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors Recruiting USA 0
NCT06400472 Phase I LY4170156 A Study of LY4170156 in Participants With Selected Advanced Solid Tumors Recruiting USA | FRA | ESP | AUS 2
NCT06412120 FDA approved Niraparib Study Evaluating Safety, Tolerability, and Metabolism of Niraparib Not yet recruiting USA 0
NCT06416436 Phase I Atezolizumab Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients Not yet recruiting USA 0
NCT06458712 Phase I DSB2455 Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies Recruiting ESP 0
NCT06465069 Phase I LY4052031 A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (NEXUS-01) Recruiting USA | GBR | ESP 1
NCT06466187 Phase I SGN-MesoC2 A Study of SGN-MesoC2 in Advanced Solid Tumors Recruiting USA 0
NCT06515613 Phase I CTIM-76 A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors Recruiting USA 0
NCT06526819 Phase Ib/II SMP-3124 A Phase 1/2 Study of SMP-3124LP in Adults With Advanced Solid Tumors Recruiting USA 1
NCT06533332 Phase I ERX-315 A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors Recruiting AUS 0
NCT06548672 Phase I BC3195 A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer Recruiting USA 0
NCT06582017 Phase I QXL138AM Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma Recruiting USA 0
NCT06586957 Phase I NKT3964 A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors Recruiting USA 0
NCT06597721 Phase I AMT-754 AMT-754 in Patients With Selected Advanced Solid Tumours Not yet recruiting AUS 0
NCT06620029 Phase Ib/II BMX-001 + Paclitaxel BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer Not yet recruiting USA 0
NCT06630325 Phase II Fulvestrant Olaparib + Pegylated liposomal doxorubicin Abemaciclib + Letrozole Abemaciclib Olaparib Olaparib + Temozolomide Abemaciclib + Tamoxifen Abemaciclib + Gemcitabine Gefitinib Abemaciclib + Pemetrexed Disodium Abemaciclib + Exemestane Osimertinib Carboplatin + Gefitinib + Pemetrexed Disodium Carboplatin + Olaparib + Paclitaxel A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced, Recurrent Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer Not yet recruiting USA 0
NCT06646627 Phase I B7-H3 CAR T cells Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors Not yet recruiting USA 0
NCT06651593 Phase II BND-22 + Cemiplimab Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors Not yet recruiting USA 0